{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:47:55Z","timestamp":1791485275831,"version":"4.3.4"},"reference-count":21,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Grhta"],"abstract":"<jats:p>Introduction: Urinary tract infections (UTIs) are common complications in patients with spinal cord injuries (SCI)and multiple sclerosis (MS), especially those using intermittent catheterization (IC) for neurogenic bladder management. These infections impact quality of life and place a burden on healthcare systems. This study aimedto provide a preliminary estimate of the burden and management of UTIs in SCI and MS patients across Italianhealthcare settings.Methods: A structured survey, developed and validated by an expert panel, was distributed to clinicians fromvarious Italian centers. It collected information on diagnostic and therapeutic approaches, risk perception, andprevention strategies for UTIs in tetraplegic\/paraplegic SCI and MS patients. The economic impact was estimatedusing the ABC methodology, considering resource utilization, antibiotic use, diagnostic tests, and managementof adverse events.Results: Survey data revealed a variability across centers. UTIs affected 75.0% of tetraplegic and 67.5% of paraplegic patients during post-trauma hospitalization, and 45.7% of MS patients. Mean hospital stay was longer for tetraplegic (137.3 days) than paraplegic patients (99.1 days). First-line antibiotic choices differed widely, andsecond-line treatments were required in 47.1% of SCI and 28.4% of MS cases. The estimated mean cost of UTImanagement was \u20ac 1,141.59 for tetraplegic, \u20ac 979.85 for paraplegic, and \u20ac 850.37 for MS patients.Conclusion: This study offers an initial overview of the clinical and economic burden of UTIs in SCI and MS patientsin Italy, revealing significant heterogeneity in management. Limitations include the small sample size andthe reliance on clinicians\u2019 perceptions rather than real-world data.<\/jats:p>","DOI":"10.33393\/grhta.2025.3607","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T07:37:56Z","timestamp":1764920276000},"page":"249-255","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and economic burden of urinary tract infections in patients with spinal cord injury and multiple sclerosis in Italy"],"prefix":"10.33393","volume":"12","author":[{"given":"Filippo","family":"Rumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8199-068X","authenticated-orcid":false,"given":"Agostino","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7964-3348","authenticated-orcid":false,"given":"Eugenio","family":"Di Brino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9294-1241","authenticated-orcid":false,"given":"Debora","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0807-4934","authenticated-orcid":false,"given":"Luisa","family":"De Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Del Popolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Gruppo GSC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18642","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"18098","doi-asserted-by":"crossref","unstructured":"Nakipoglu GF, Kaya AZ, Orhan G, et al. Urinary dysfunction in multiple sclerosis. J Clin Neurosci. 2009;16(10):1321-1324. PMID:19560927 https:\/\/doi.org\/10.1016\/j.jocn.2008.12.012 PMID:19560927","DOI":"10.1016\/j.jocn.2008.12.012"},{"key":"18099","doi-asserted-by":"crossref","unstructured":"Maghzi AH, Minagar A. Urinary tract infection in multiple sclerosis: a practical algorithm for a common problem. Eur J Neurol. 2013;20(3):408-409. PMID:22900671 https:\/\/doi.org\/10.1111\/j.1468-1331.2012.03833.x PMID:22900671","DOI":"10.1111\/j.1468-1331.2012.03833.x"},{"key":"18100","doi-asserted-by":"crossref","unstructured":"Mukai S, Shigemura K, Nomi M, et al. Retrospective study for risk factors for febrile UTI in spinal cord injury patients with routine concomitant intermittent catheterization in outpatient settings. Spinal Cord. 2016;54(1):69-72. PMID:26458969 https:\/\/doi.org\/10.1038\/sc.2015.170 PMID:26458969","DOI":"10.1038\/sc.2015.170"},{"key":"18101","doi-asserted-by":"crossref","unstructured":"Dedei\u0107-Ljubovi\u0107 A, Huki\u0107 M. Catheter-related urinary tract infection in patients suffering from spinal cord injuries. Bosn J Basic Med Sci. 2009;9(1):2-9. PMID:19284388 https:\/\/doi.org\/10.17305\/bjbms.2009.2849 PMID:19284388","DOI":"10.17305\/bjbms.2009.2849"},{"key":"18102","doi-asserted-by":"crossref","unstructured":"He Y, Zhao J, Wang L, et al. Epidemiological trends and predictions of urinary tract infections in the global burden of disease study 2021. Sci Rep. 2025;15(1):4702. https:\/\/doi.org\/10.1038\/s41598-025-89240-5 PMID:39922870","DOI":"10.1038\/s41598-025-89240-5"},{"key":"18103","doi-asserted-by":"crossref","unstructured":"Keel G, Savage C, Rafiq M, Mazzocato P. Time-driven activity-based costing in health care: A systematic review of the literature. Health Policy. 2017;121(7):755-763. PMID:28535996 https:\/\/doi.org\/10.1016\/j.healthpol.2017.04.013 PMID:28535996","DOI":"10.1016\/j.healthpol.2017.04.013"},{"key":"18104","unstructured":"Agenzia Italiana del Farmaco (AIFA). Ciprofloxacina. Online https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=CIPROFLOXACINA%20(PRINCIPIO%20ATTIVO)&exact=true (Accessed July 2025)"},{"key":"18105","unstructured":"Agenzia Italiana del Farmaco (AIFA). Levofloxacina. Online https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=LEVOFLOXACINA%20(PRINCIPIO%20ATTIVO)&exact=true (Accessed July 2025)"},{"key":"18106","unstructured":"Agenzia Italiana del Farmaco (AIFA). Cefixima. Online https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=CEFIXIMA%20(PRINCIPIO%20ATTIVO)&exact=true (Accessed July 2025)"},{"key":"18107","unstructured":"Agenzia Italiana del Farmaco (AIFA). Riassunto delle Caratteristiche del Prodotto. Ceftriaxone. Online https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=CEFTRIAXONE%20(PRINCIPIO%20ATTIVO)&exact=true (Accessed July 2025)"},{"key":"18108","unstructured":"Agenzia Italiana del Farmaco (AIFA). Amikacina. Online https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=AMIKACINA%20(PRINCIPIO%20ATTIVO)&exact=true (Accessed July 2025)"},{"key":"18109","unstructured":"Agenzia Italiana del Farmaco (AIFA). Gentamicina. Online https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=GENTAMICINA%20(PRINCIPIO%20ATTIVO)&exact=true (Accessed July 2025)"},{"key":"18110","unstructured":"Agenzia Italiana del Farmaco (AIFA). Nitrofurantoina. Online https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=NITROFURANTOINA%20(PRINCIPIO%20ATTIVO)&exact=true (Accessed July 2025)"},{"key":"18111","unstructured":"Agenzia Italiana del Farmaco (AIFA). Fosfomicina. Online https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=FOSFOMICINA%20(PRINCIPIO%20ATTIVO)&exact=true (Accessed July 2025)"},{"key":"18112","unstructured":"Agenzia Italiana del Farmaco (AIFA). Antibiotici Beta-lattamici (es. Amoxicillina, Piperacillina\/Tazobactam). Online https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=AMOXICILLINA%20ACIDO%20CLAVULANICO%20TEVA%20(MEDICINALE)&exact=true (Accessed July 2025)"},{"key":"18113","unstructured":"Tariffe DRG. (Diagnosis Related Groups) Ministero della Salute. Sistema di classificazione e tariffazione dei DRG in Italia. Online https:\/\/www.salute.gov.it\/new\/it\/tema\/assistenza-ospedaliera\/principali-caratteristiche-diagnosis-related-groups-drg\/ (Accessed July 2025)"},{"key":"18114","unstructured":"Nomenclatore delle prestazioni ambulatoriali specialistiche Ministero della Salute. Nomenclatore tariffario delle prestazioni di assistenza specialistica ambulatoriale. Online https:\/\/www.salute.gov.it\/new\/it\/tema\/programmazione-e-finanziamento-del-ssn\/tariffari-nazionali-delle-prestazioni-del-ssn\/?paragraph=0#body (Accessed July 2025)"},{"key":"18115","unstructured":"Liste di trasparenza AIFA (costo farmaci) Agenzia Italiana del Farmaco (AIFA). Liste di trasparenza e rimborsabilit\u00e0 dei medicinali. Online https:\/\/www.aifa.gov.it\/liste-di-trasparenza (Accessed July 2025)"},{"key":"18116","unstructured":"AIFA medicinali, ricerca un farmaco. Online https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/ (Accessed July 2025)"},{"key":"18117","unstructured":"Groen J, Pannek J, Castro-Diaz D, et al. EAU Guidelines on Neuro-Urology 2024. European Association of Urology. Online https:\/\/uroweb.org\/guidelines\/neuro-urology (Accessed July 2025)"},{"key":"18118","doi-asserted-by":"crossref","unstructured":"Cameron AP, et al. Intermittent catheterization with hydrophilic-coated catheters reduces the risk of urinary tract infections compared with uncoated catheters in patients with spinal cord injury: a systematic review and meta-analysis. Spinal Cord. 2013;51(11):784-789. PMID:23807320 https:\/\/doi.org\/10.1038\/sc.2013.87","DOI":"10.1038\/sc.2013.87"}],"container-title":["Global and Regional Health Technology Assessment"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3607\/4158","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3607\/4159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3607\/4159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T07:38:01Z","timestamp":1764920281000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/view\/3607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,15]]}},"URL":"https:\/\/doi.org\/10.33393\/grhta.2025.3607","relation":{},"ISSN":["2283-5733","2284-2403"],"issn-type":[{"value":"2283-5733","type":"electronic"},{"value":"2284-2403","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,4]]}}}